title: Imatinib mesylate-induced pseudoporphyria in two children.
abstract: Imatinib mesylate was the first of several tyrosine kinase inhibitors approved for use in the treatment of a number of human cancers. Adverse cutaneous reactions to imatinib are common. Pseudoporphyria has been infrequently reported in adults undergoing imatinib therapy for chronic myeloid leukemia. We present two children with pseudoporphyria induced by imatinib therapy for hematologic malignancies. In view of the burgeoning use of imatinib in children, physicians should be aware that pseudoporphyria may develop as a consequence of imatinib therapy.
authors.affiliation: Department of Paediatric Dermatology, Starship Children's Health, Auckland, New Zealand.
authors.forename: Caroline
authors.initials: C
authors.lastname: Mahon
authors.forename: Diana
authors.initials: D
authors.lastname: Purvis
authors.forename: Stephen
authors.initials: S
authors.lastname: Laughton
authors.forename: Peter
authors.initials: P
authors.lastname: Bradbeer
authors.forename: Lochie
authors.initials: L
authors.lastname: Teague
mesh_terms: D000293:Adolescent; D000970:Antineoplastic Agents / Q000009:adverse effects*; D001549:Benzamides / Q000009:adverse effects*; D002648:Child; D003875:Drug Eruptions / Q000209:etiology*; D005260:Female; D006801:Humans; D000068877:Imatinib Mesylate; D015464:Leukemia, Myelogenous, Chronic, BCR-ABL Positive / Q000188:drug therapy*; D010879:Piperazines / Q000009:adverse effects*; D054198:Precursor Cell Lymphoblastic Leukemia-Lymphoma / Q000188:drug therapy*; D011743:Pyrimidines / Q000009:adverse effects*
chemical_list: D000970:Antineoplastic Agents; D001549:Benzamides; D010879:Piperazines; D011743:Pyrimidines; D000068877:Imatinib Mesylate